NCT04059913 - Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease | Biotech Hunter

Enrollment

318

Participants

Timeline

Start Date

June 11, 2019

Primary Completion Date

November 19, 2021

Study Completion Date

December 17, 2021

Conditions

CKD Anemia in Dialysis Participants

Interventions

DRUG

Roxadustat

Roxadustat will be dosed orally per dose and schedule specified in the arm description.

Trial Locations (25)

100044

Investigational Site, Beijing

100191

Investigational Site, Beijing

100730

Investigational Site, Beijing

110004

Investigational Site, Shenyang

110122

Investigational Site, Shenyang

130021

Investigational Site, Changchun

200025

Investigational Site, Shanghai

210009

Investigational Site, Nanjing

230601

Investigational Site, Hefei

300052

Investigational Site, Tianjin

310003

Investigational Site, Hangzhou

330006

Investigational Site, Nanchang

410008

Investigational Site, Changsha

430060

Investigational Site, Wuhan

450052

Investigational Site, Zhengzhou

510515

Investigational Site, Guangzhou

518020

Investigational Site, Shenzhen

530021

Investigational Site, Nanning

610041

Investigational Site, Chengdu

610072

Investigational Site, Chengdu

710004

Investigational Site, Xi’an

710061

Investigational Site, Xi’an

730030

Investigational Site, Lanzhou

014010

Investigational Site, Baotou

030001

Investigational Site, Taiyuan